EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection

Boshu Chen, José Victor Zambrana iD, Abigail Shotwell, Nery Sanchez, Miguel Plazaola, Sergio Ojeda, Roger Lopez, Daniel Stadlbauer, Guillermina Kuan, Angel Balmaseda, Florian Krammer iD, Aubree Gordon iD

Influenza and Other Respiratory Viruses · 2026-07 · 20 (7)

DOI: 10.1111/irv.70292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 12.07.2026. Verfasst von Boshu Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Influenza A Virus, H3N2 Subtype, Antibodies, Viral, Influenza, Human. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ODCDC CDC HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although the hemagglutination inhibition (HAI) titer remains the gold standard correlate of protection against influenza, it does not fully capture the broader antibody responses that contribute to immunity.

Methods

We analyzed immune responses in paired pre‐infection and convalescent sera from 306 RT‐PCR–confirmed A(H3N2) infections from two household studies (2014–2018) in Managua, Nicaragua. Antibody responses were measured by HAI and enzyme‐linked immunosorbent assays (ELISAs) against full‐length hemagglutinin (HA), the HA stalk, and neuraminidase (NA). Participants were classified as HAI responders (≥ 4‐fold HAI rise), alternate responders (no HAI rise but ≥ 4‐fold boost in ≥ 1 ELISA), or no‐response individuals (no ≥ 4‐fold rise in any assay). We compared demographic, clinical, and pre‐infection antibody characteristics across these groups. We also analyzed predictors of an NA response.

Results

Overall, 77% of participants had HAI seroconversion or a fourfold rise. Among the 23% HAI non‐responders, 62% had alternate antibody responses. No‐response individuals had the highest pre‐infection HAI and full‐length HA titers ( p < 0.01), the lowest viral loads, and the lowest frequency of fever or influenza‐like illness symptoms ( p < 0.01). An NA response was more common among symptomatic individuals and moderate baseline titers, with both low and high extremes reducing NA response odds.

Conclusions

High baseline HAI titers can limit detectable fourfold rises and are associated with milder illness. Evaluating additional immune responses may capture a more complete picture of the host response to infection, thereby improving surveillance and informing vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H3N2 SubtypeAntibodies, ViralInfluenza, HumanHumansHemagglutination Inhibition TestsFemaleMaleNeuraminidaseAdultNicaraguaMiddle AgedEnzyme-Linked Immunosorbent AssayYoung AdultAdolescentHemagglutinin Glycoproteins, Influenza Virus

Stichwörter der Autor:innen

correlates of protectionhemagglutination inhibition (HAI)influenza A/H3N2neuraminidase antibodiessymptomatic versus asymptomatic infection

Substanzen

Antibodies, ViralNeuraminidaseHemagglutinin Glycoproteins, Influenza Virus

Autor:innen und Institutionen

  • Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
  • Sustainable Sciences Institute, Managua, Nicaragua.
  • Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.
  • Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: José Victor Zambrana, Florian Krammer, Aubree Gordon

Förderung

  • ODCDC CDC HHS
  • NIAID NIH HHS
  • NIH HHS
  • Flu Lab
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Chen, B., Zambrana, J. V., Shotwell, A., Sanchez, N., Plazaola, M., Ojeda, S., Lopez, R., Stadlbauer, D., Kuan, G., Balmaseda, A., Krammer, F., & Gordon, A. (2026). Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection. Influenza and Other Respiratory Viruses, 20(7). https://doi.org/10.1111/irv.70292

Vancouver

Chen B, Zambrana JV, Shotwell A, Sanchez N, Plazaola M, Ojeda S, et al. Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection. Influenza and Other Respiratory Viruses. 2026;20(7). doi:10.1111/irv.70292

BibTeX
@article{Chen2026,
  author = {Chen, Boshu and Zambrana, José Victor and Shotwell, Abigail and Sanchez, Nery and Plazaola, Miguel and Ojeda, Sergio and Lopez, Roger and Stadlbauer, Daniel and Kuan, Guillermina and Balmaseda, Angel and Krammer, Florian and Gordon, Aubree},
  title = {Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  volume = {20},
  number = {7},
  doi = {10.1111/irv.70292}
}
Kostenlos starten →